Professor | Jia Wei | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Jia Wei
Contact Information	jiawei99@nju.edu.cn
Language ability	English, Chinese
Province	Jiangsu

Upload Avatar (500 x 500)

Name

Jia Wei

Contact Information

jiawei99@nju.edu.cn

Language ability

English, Chinese

Province

Jiangsu

University/Lab Affiliation and Title	Nanjing University
Faculty	Medical School
Academic Background & Achievements	Ph.D. in Medical Oncology: Nanjing University Fellow: Harvard Medical School/Massachusetts General Hospital/Dana-Farber Cancer Institute Youth Scholar: Ministry of Education's Changjiang Scholars Program Chief Scientist: Major Special Project of Science and Technology, Ministry of Science and Technology
Work Experience	Current - Nanjing University Medical School Affiliated Drum Tower Hospital - Chief Physician/Professor Current - Nanjing University Clinical Cancer Research Institute - Deputy Director Current - eLife Journal - Editor Current - BMC Cancer, Translational Cancer Research, Frontiers in Oncology - Editorial Board Member
Awards	2020: Youth Scholar, Ministry of Education's Changjiang Scholars Program 2020: China Youth May Fourth Medal 2020: Young Scientist in Oncology, China 2020: Wu Mengchao Medical Youth Fund Award 2020: People's Good Doctor (Gastric Cancer Field) Jinshan Camellia Outstanding Contribution Award 2020: Second Prize, Jiangsu Province New Technology Introduction 2019: First Prize, Jiangsu Province Science and Technology Award 2019: First Prize, Jiangsu Province Medical Science and Technology Award 2018: JSMO 2018 Young Investigator Award 2017: Second Prize, Ministry of Education Science and Technology Progress Award 2015: First Prize, Jiangsu Province New Technology Introduction Award 2015: Third Prize, Chinese Medical Award 2015: Second Prize, Jiangsu Province Science and Technology Award 2015: Second Prize, Jiangsu Province Medical Science and Technology Award 2012: Second Prize, Jiangsu Province Science and Technology Award 2011: Second Prize, Chinese Medical Science and Technology Award 2012: Second Prize, China Anti-Cancer Association Science and Technology Award 2011: Second Prize, Jiangsu Province Medical Science and Technology Award 2008: Third Prize, China Oncology Conference 2007: First Prize, Jiangsu Province New Technology Introduction Award

University/Lab Affiliation and Title

Nanjing University

Faculty

Medical School

Academic Background & Achievements

Ph.D. in Medical Oncology: Nanjing University
Fellow: Harvard Medical School/Massachusetts General Hospital/Dana-Farber Cancer Institute
Youth Scholar: Ministry of Education's Changjiang Scholars Program
Chief Scientist: Major Special Project of Science and Technology, Ministry of Science and Technology

Work Experience

Current - Nanjing University Medical School Affiliated Drum Tower Hospital - Chief Physician/Professor
Current - Nanjing University Clinical Cancer Research Institute - Deputy Director
Current - eLife Journal - Editor
Current - BMC Cancer, Translational Cancer Research, Frontiers in Oncology - Editorial Board Member

Awards

2020: Youth Scholar, Ministry of Education's Changjiang Scholars Program
2020: China Youth May Fourth Medal
2020: Young Scientist in Oncology, China
2020: Wu Mengchao Medical Youth Fund Award
2020: People's Good Doctor (Gastric Cancer Field) Jinshan Camellia Outstanding Contribution Award
2020: Second Prize, Jiangsu Province New Technology Introduction
2019: First Prize, Jiangsu Province Science and Technology Award
2019: First Prize, Jiangsu Province Medical Science and Technology Award
2018: JSMO 2018 Young Investigator Award
2017: Second Prize, Ministry of Education Science and Technology Progress Award
2015: First Prize, Jiangsu Province New Technology Introduction Award
2015: Third Prize, Chinese Medical Award
2015: Second Prize, Jiangsu Province Science and Technology Award
2015: Second Prize, Jiangsu Province Medical Science and Technology Award
2012: Second Prize, Jiangsu Province Science and Technology Award
2011: Second Prize, Chinese Medical Science and Technology Award
2012: Second Prize, China Anti-Cancer Association Science and Technology Award
2011: Second Prize, Jiangsu Province Medical Science and Technology Award
2008: Third Prize, China Oncology Conference
2007: First Prize, Jiangsu Province New Technology Introduction Award

Areas of Focus	Personalized Treatment of Gastric Cancer Tumor Immunotherapy
Publications	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors, Chen F, Zou Z, Du J, Su S, Shao J, Meng F, Yang J, Xu Q, Ding N, Yang Y, Liu Q, Wang Q, Sun Z, Zhou S, Du S, Wei J, Liu B, 2019 iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer, Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, Chen F, Du S, Zhou S, Chen H, Zhang L, Yang J, Wei J, Liu B, 2019 DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer, Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X, Liang K, Luo Y, Che K, Wang X, Pan Y, Liu F, Yang J, Liu Q, Yu L, Liu B, Wei J, 2022 Nitric Oxide-Driven Nanomotor for Deep Tissue Penetration and Multidrug Resistance Reversal in Cancer Therapy, Wan MM, Chen H, Da Wang Z, Liu ZY, Yu YQ, Li L, Miao ZY, Wang XW, Wang Q, Mao C, Shen J, Wei J, 2020 Deep Penetration of Nanolevel Drugs and Micrometer-Level T Cells Promoted by Nanomotors for Cancer Immunochemotherapy, Chen H, Shi T, Wang Y, Liu Z, Liu F, Zhang H, Wang X, Miao Z, Liu B, Wan M, Mao C, Wei J, 2021 Systematic Research and Evaluation Models of Nanomotors for Cancer Combined Therapy, Wan M, Wang Q, Li X, Xu B, Fang D, Li T, Yu Y, Fang L, Wang Y, Wang M, Wang F, Mao C, Shen J, Wei J, 2020 Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation, Zhou S, Meng F, Du S, Qian H, Ding N, Sha H, Zhu M, Yu X, Wang L, Liu B, Wei J, 2021 Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study, Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, Zhang X, Fan N, Luo S, Li Z, Gu K, Lu J, Xu J, Fan Q, Xu R, Zhang L, Li E, Sun Y, Yu G, Bai C, Liu Y, Zeng J, Ying J, Liang X, Xu N, Gao C, Shu Y, Ma D, Dai G, Li S, Deng T, Cui Y, Fang J, Ba Y, Shen L, 2021 NIR-Activated Multimodal Photothermal/Chemodynamic/Magnetic Resonance Imaging Nanoplatform for Anticancer Therapy by Fe(II) Ions Doped MXenes (Fe-Ti3 C2 ), Wu Y, Song X, Xu W, Sun KY, Wang Z, Lv Z, Wang Y, Wang Y, Zhong W, Wei J, Cai HL, Wu X, 2021 Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K, Cheng Y, Yuan X, Xiao J, Tai Y, Wang L, Zou J, Zhang Y, Shen L, 2021 Two biomarker-directed randomized trials in European and Chinese patients with non-small-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies, Moran T, Wei J, Cobo M, et al, 2014 Tumor neoantigens: from basic research to clinical applications, Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, Ren S, Zhou C, 2019 mRNA Expression of BRCA1, PIAS1, and PIAS4 and Survival After Second-line Docetaxel in Advanced Gastric Cancer, Wei J, Costa C, Ding Y, et al, 2011

Areas of Focus

Personalized Treatment of Gastric Cancer
Tumor Immunotherapy

Publications

Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors, Chen F, Zou Z, Du J, Su S, Shao J, Meng F, Yang J, Xu Q, Ding N, Yang Y, Liu Q, Wang Q, Sun Z, Zhou S, Du S, Wei J, Liu B, 2019
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer, Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, Chen F, Du S, Zhou S, Chen H, Zhang L, Yang J, Wei J, Liu B, 2019
DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer, Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X, Liang K, Luo Y, Che K, Wang X, Pan Y, Liu F, Yang J, Liu Q, Yu L, Liu B, Wei J, 2022
Nitric Oxide-Driven Nanomotor for Deep Tissue Penetration and Multidrug Resistance Reversal in Cancer Therapy, Wan MM, Chen H, Da Wang Z, Liu ZY, Yu YQ, Li L, Miao ZY, Wang XW, Wang Q, Mao C, Shen J, Wei J, 2020
Deep Penetration of Nanolevel Drugs and Micrometer-Level T Cells Promoted by Nanomotors for Cancer Immunochemotherapy, Chen H, Shi T, Wang Y, Liu Z, Liu F, Zhang H, Wang X, Miao Z, Liu B, Wan M, Mao C, Wei J, 2021
Systematic Research and Evaluation Models of Nanomotors for Cancer Combined Therapy, Wan M, Wang Q, Li X, Xu B, Fang D, Li T, Yu Y, Fang L, Wang Y, Wang M, Wang F, Mao C, Shen J, Wei J, 2020
Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation, Zhou S, Meng F, Du S, Qian H, Ding N, Sha H, Zhu M, Yu X, Wang L, Liu B, Wei J, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study, Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, Zhang X, Fan N, Luo S, Li Z, Gu K, Lu J, Xu J, Fan Q, Xu R, Zhang L, Li E, Sun Y, Yu G, Bai C, Liu Y, Zeng J, Ying J, Liang X, Xu N, Gao C, Shu Y, Ma D, Dai G, Li S, Deng T, Cui Y, Fang J, Ba Y, Shen L, 2021
NIR-Activated Multimodal Photothermal/Chemodynamic/Magnetic Resonance Imaging Nanoplatform for Anticancer Therapy by Fe(II) Ions Doped MXenes (Fe-Ti3 C2 ), Wu Y, Song X, Xu W, Sun KY, Wang Z, Lv Z, Wang Y, Wang Y, Zhong W, Wei J, Cai HL, Wu X, 2021
Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K, Cheng Y, Yuan X, Xiao J, Tai Y, Wang L, Zou J, Zhang Y, Shen L, 2021
Two biomarker-directed randomized trials in European and Chinese patients with non-small-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies, Moran T, Wei J, Cobo M, et al, 2014
Tumor neoantigens: from basic research to clinical applications, Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, Ren S, Zhou C, 2019
mRNA Expression of BRCA1, PIAS1, and PIAS4 and Survival After Second-line Docetaxel in Advanced Gastric Cancer, Wei J, Costa C, Ding Y, et al, 2011

Gastric Cancer Personalized Medicine Molecular Typing Neoantigen Cell Therapy Immunotherapy Clinical Research Oncology Cancer Treatment Medical Research

Xu Yang - Southern University of Science and Technology

Yong Huang - Wuhan University

Qingyun Wang - Wuhan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us